How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Data on medicinal plants used in Central America to manage diabetes and its sequelae (skin conditions, cardiovascular disease, kidney disease, urinary problems and vision loss) Full Text available with Trip Pro

Data on medicinal plants used in Central America to manage diabetes and its sequelae (skin conditions, cardiovascular disease, kidney disease, urinary problems and vision loss) The data described in this article is related to the review article "Medicinal plants used in the traditional management of diabetes and its sequelae in Central America: a review" (Giovannini et al., 2016) [1]. We searched publications on the useful plants of Central America in databases and journals by using selected (...) relevant keywords. We then extracted reported uses of medicinal plants within the disease categories: diabetes mellitus, kidney disease, urinary problems, skin diseases and infections, cardiovascular disease, sexual dysfunction, vision loss, and nerve damage. The following countries were included in our definition of Central America: Belize, Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica and Panama. Data were compiled in a bespoke Access database. Plant names from the published sources were

2016 Data in brief

42. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

inhibitors, SGLT-2 inhibitors, and SGLT-1/SGLT-2 inhibitors may be considered experimental drugs being tested for adjunctive therapy in T1D adult patients. As such, their place in therapy in the management of T1D still needs to be defined. Background Diabetes mellitus is a metabolic disorder that results from defects in insulin secretion, insulin action, or both. 1 There are two major categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin (...) .) Note: Table adapted from Table 7 in Endocrine and Metabolic Disorders: Diabetes Mellitus Chapter of Therapeutic Choices. © Canadian Pharmacists Association, 2016. All rights reserved. Source: . Accessed: November 30, 2016. Other information sources include the Government of Canada Notice of Compliance Database 29 and the Government of Canada Drug and Health Product Register. 34 Patient Group Insulin is a life-saving drug for T1D patients. 10 However, some T1D patients have difficulty obtaining

2018 CADTH - Issues in Emerging Health Technologies

43. Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2015 Clinical Trials

44. The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus

The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect (...) of Shear- Force at the Skin in Patients With Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02348294 Recruitment Status : Unknown Verified January 2015 by Maastricht University Medical Center. Recruitment status was: Not yet recruiting First Posted : January 28, 2015 Last Update

2015 Clinical Trials

45. Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes

Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes Published December 2019 Volume 19, Number 8 ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes: A Health Technology Assessment KEY MESSAGES What Is This Health Technology Assessment About? Diabetes is a health condition in which the pancreas cannot produce any insulin, the pancreas cannot produce enough insulin, or the body cannot properly use the insulin (...) the pancreas does produce. Insulin is a hormone that helps the body’s cells use glucose (a type of sugar) for energy. Without insulin, glucose builds up in the blood and can cause serious damage to the body. Type 1 diabetes occurs when the pancreas produces little or no insulin. Type 2 diabetes occurs when the pancreas does not produce enough insulin or when the body does not respond to insulin properly. People with diabetes have a greater risk of being sent to hospital with life-threating conditions

2019 Health Quality Ontario

46. Diabetic Foot Infections

foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9):2819-2828. 31. Rathsman B, Jensen-Urstad K, Nystrom T. Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: A long-term follow-up study. Diabetologia. 2014;57(8):1703-1710. 32. Ang Y, Yap C, Saxena N, Lin L, Heng B. Diabetes- related lower extremity amputations in singapore. . 2016. (...) diabetic foot infection is summarized in Figure 1. History should focus on acuity and severity of the infection and physical exam should assess the skin, vascular, neurological and musculoskeletal systems. [I-C] Grading of severity can be done using the Infectious Diseases Society of America classification scheme (Table 1). [I-C] Ankle Brachial Index and Toe Brachial Index (ABI/TBI) measurements should be taken to evaluate for underlying peripheral vascular disease. Perform an initial x-ray to evaluate

2020 University of Michigan Health System

47. CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM) CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. CS02 vs Placebo (...) With Metformin in Type 2 Diabetes Mellitus (T2DM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03317028 Recruitment Status : Recruiting First Posted : October 23, 2017 Last Update Posted : December 18, 2018 See Sponsor: Center

2017 Clinical Trials

48. Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

(SBP) for all patients; and to evaluate the proportion of patients with a HbA1C <7%. To demonstrate the superiority of sotagliflozin dose 2 versus placebo with respect to HbA1c reduction; change in BW, FPG, and SBP for all patients; and to evaluate the proportion of patients with HbA1c <7.0%. To evaluate the safety of sotagliflozin dose 1 and dose 2 compared with placebo. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sotagliflozin (SAR439954) Drug: Placebo Phase 3 (...) Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2017 Clinical Trials

49. Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

of patients with HbA1c <6.5% and <7.0%, and on sitting systolic blood pressure (SBP) reduction. To demonstrate the superiority of sotagliflozin versus empagliflozin on HbA1c reduction and sitting SBP reduction. To evaluate the safety of sotagliflozin versus empagliflozin, and placebo, throughout the trial. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sotagliflozin (SAR439954) Drug: Empagliflozin Drug: Placebo Phase 3 Detailed Description: Up to 34 weeks, including (...) Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2017 Clinical Trials

50. Ketoacidosis in Neonatal Diabetes Mellitus, Part of Wolcott-Rallison Syndrome Full Text available with Trip Pro

Ketoacidosis in Neonatal Diabetes Mellitus, Part of Wolcott-Rallison Syndrome BACKGROUND Neonatal diabetes mellitus is a rare condition and it is important to differentiate it from other causes, such as hyperglycemia in infancy, for better outcomes. We report a case of an infant who presented to our neonatal intensive care unit in ketoacidosis and a comatose state. CASE REPORT Our case was an infant who presented to the neonatal intensive care unit at 38 days of age in ketoacidosis. The female (...) daily via subcutaneous route. A few days later, blood samples were sent from our hospital in India to the UK and genetic testing was performed free of charge by the Department of Molecular Genetics, University of Exeter Medical School, UK, and confirmed a genetic diagnosis of Wolcott-Rallison syndrome. CONCLUSIONS Regardless of whether permanent neonatal diabetes mellitus is associated with Wolcott-Rallison syndrome or other genetic mutations, it is important to initially stabilize the infant

2017 The American journal of case reports

51. Evaluation of Compression Therapy in Patients With Mild to Moderate PAD or Diabetes Mellitus

Posted : December 27, 2017 Last Update Posted : December 27, 2017 See Sponsor: University Hospital Erlangen Information provided by (Responsible Party): Ulrich Rother, University Hospital Erlangen Study Details Study Description Go to Brief Summary: Aim of this prospective clinical study is the Evaluation of the Effect of Compression Therapy on the Microcirculation in Patients With Leg Edema and Mild to Moderate PAD or Diabetes Mellitus. Condition or disease Intervention/treatment Phase Peripheral (...) Evaluation of Compression Therapy in Patients With Mild to Moderate PAD or Diabetes Mellitus Evaluation of Compression Therapy in Patients With Mild to Moderate PAD or Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

52. Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus

staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with Diabetes mellitus with active Charcot neuroarthropathy of foot as per following criteria: Clinical criteria Warm, swollen and erythematous foot Skin temperature exceeding 2°C at the clinically suspected site of the affected (...) Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

53. Wireless Innovation for Seniors With Diabetes Mellitus

Diabetes Research Foundation Information provided by (Responsible Party): Jaeb Center for Health Research Study Details Study Description Go to Brief Summary: The primary objective of the study is to determine if CGM can reduce hypoglycemia and improve quality of life in older adults with T1D. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Device: Dexcom CGM Not Applicable Detailed Description: Reducing hypoglycemia is an important aspect of management of T1D in older adults (...) Wireless Innovation for Seniors With Diabetes Mellitus Wireless Innovation for Seniors With Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Wireless Innovation for Seniors With Diabetes

2017 Clinical Trials

54. A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Update Posted : February 8, 2018 Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Study Description Go to Brief Summary: A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus. Approximately 63 subjects will be enrolled across two cohorts. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: MEDI0382 Drug (...) A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

55. Home-based Proprioceptive Neuromuscular Facilitation for Subjects With Type 2 Diabetes Mellitus

of the upper extremity of patients with diabetes mellitus. And,the other is home-based PNF in conjunction with TGE provides better benefits for neuromuscular function of the upper extremity of patients with diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Mellitus Exercise Behavioral: lifestyle changes Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 12 participants Allocation: Randomized (...) criteria of the enrolled subjects are who suffered from neuropathy as diagnosed by abnormalities in either a nerve conduction study and / or quantitative sensory testing. Exclusion Criteria: DM patients with (1) traumatic nerve injuries of the upper limbs, (2) trauma to the hand or congenital anomalies of the wrist and hand, (3) skin infections or disease, (4) known vascular complications of diabetes, such as stroke may have compromised the physical integrity of the patient, (5) grade 2 or higher

2017 Clinical Trials

56. Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

the safety of sotagliflozin doses 1 and 2 versus placebo. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: sotagliflozin (SAR439954) Drug: insulin glargine (HOE901) Drug: Placebo Phase 3 Detailed Description: Up to 60 weeks (Screening phase of up to 2 weeks, a 4-week Lantus titration/single-blind placebo Run-in phase), a 52-week double blind Treatment Period, and a 2-week post-treatment Follow-up Period. Study Design Go to Layout table for study information Study Type (...) Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2017 Clinical Trials

57. Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 731 participants Allocation: Randomized Intervention Model (...) Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

58. Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

: January 5, 2017 Last Update Posted : October 17, 2018 See Sponsor: Second Xiangya Hospital of Central South University Information provided by (Responsible Party): Zhiguang Zhou, Second Xiangya Hospital of Central South University Study Details Study Description Go to Brief Summary: The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Autoimmune Diabetes Drug: Liraglutide (...) Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

59. A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended to allow for a full 36 weeks (maintenance 2 period) of the use of the new process. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus (...) A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary

2017 Clinical Trials

60. Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

in three predefined, increasing doses in each panel, or glargine (active comparator). The primary hypothesis of the trial is that at a dose with sufficient safety, the mean steady-state maximum level of glucose infusion rate (GIRmax) after MK-5160 administration in both T1DM and T2DM participants is between 1.5 and 4.5 mg/kg/min. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Biological: MK-5160 low dose Biological: MK-5160 medium dose Biological: MK (...) Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>